ClinicalTrials.gg

Program

REGN9220

A development code.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Oct 14, 20261 company-led study, 1 open or runningNext primary completion: Nov 1, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals11 open or runningphase 2since Oct 14, 2026Oct 14, 2026Nov 1, 2029phase 2 · NCT07887750

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2026First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT07887750 · 36 planned

Ahead

  1. Nov 1, 2029Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07887750

TargetBeta

“Phase 1 Trial to Investigate the Safety and Tolerability of REGN9220, an Anti-CD22 X Anti-4-1BB Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Aggressive B-Cell Non-Ho…”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07887750Lymphoma, Large B-Cell, Diffuse2Not yet recruitingNov 1, 202936

How it is read

Names in the registry

  • “REGN9220”, 1 entry

Codes read as this program: REGN9220.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.